数字化转型影响医药企业价值的传导路径

The Transmission Path of the Impact of Digital Transformation on the Value of Medical Enterprises

目前,数字化转型是我国医药产业高质量发展的必然选择。医药数字化转型能否提升医疗企业的价值,以及其效应通过何种路径传导,成为了我国医药企业积极推动数字化转型的重要议题。选取2011—2021年沪深两市345家上市医药企业的数据,实证检验数字化转型对医药企业价值影响的传导路径。平行中介模型实证结果表明:数字化转型主要通过研发和专利的传导路径对医药企业价值起到正面的促进作用。

At present,digital transformation is an inevitable choice for the high-quality deveopment of China's medical industry.Whether digital transformation can enhance the value of medical companies,and though which pathways the effects are transmitted have become critical issues for Chinese medical companies to actively promote digital transformation.This paper uses the data of 345 listed medical enterprises from 2011 to 2021 to empirically test the transmission path of digital transformation affecting the performance of medical enterprises.The empirical results of the parallel mediation model indicate that digital transformation mainly promotes the performance of medical enterprises through the paths of R&D and patents.